Aim: To investigate whether the preceding rate of glucose fall affects the glucose response to subcutaneous (s.c.) low-dose glucagon administration.

Methods: Ten adults with insulin pump-treated type 1 diabetes completed a randomized, single-blinded, 2-way cross-over study. Using hyperinsulinemic clamp technique, plasma glucose (PG) levels were initially stabilized at 8.0 mmol/l for ≥ 2 hrs. Thereafter, the glucose infusion rate was reduced to obtain either a rapid or a slow PG fall, while the insulin infusion was maintained at a fixed rate. When PG reached 3.9 mmol/l, insulin and glucose infusions were discontinued and a s.c. bolus of 150 µg glucagon was administered. PG levels were measured frequently for the following 120 min.

Results: The positive incremental area under the glucose curve (AUC) after administration of low-dose glucagon did not differ between the visits with a preceding rapid or slow glucose fall rate (mean ± s.e.m: 110 ± 25 vs. 73 ± 24 mmol/l x min, p = 0.21). Similarly, no significant difference in total AUC, peak PG, incremental peak PG, time-to-peak PG or PG at 120 min was observed.

Conclusions: Preceding glucose fall rate under fixed insulin level conditions did not affect the glucose response to low-dose s.c. glucagon administration.


C. Laugesen: None. S. Schmidt: Advisory Panel; Self; Medtronic. K. Nørgaard: Advisory Panel; Self; Abbott, Medtronic. Research Support; Self; Novo Nordisk A/S. Speaker’s Bureau; Self; Medtronic, Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk Inc. A. Ranjan: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at